febuxostat (uloric) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that febuxostat is less prone to excacerbate systemic inflammatory events in animal studies. Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations. Febuxostat is used for the treatment of hyperuricemia in patients with gout.   NCATS

Chemistry

  • SMILES: CC(C)COC1=C(C=C(C=C1)C2=NC(C)=C(S2)C(O)=O)C#N
  • InChIKey: BQSJTQLCZDPROO-UHFFFAOYSA-N
  • Mol. Mass: 316.375
  • ALogP: 3.72
  • ChEMBL Molecule:
    febuxostat  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.1034

United States

$1.5995 - $10.6068
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid | adenuric | februxostat | feburic | febuxostat | fébuxostat | febuxostatum | tmx-67 | uloric

Organizations (98)

Research & Development (79)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

Hyperuricemia

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Albuminuria (Phase 2)

Angina Pectoris (Phase 2)

Blood Pressure (Phase 4)

Cardiovascular Diseases (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Coronary Artery Disease (Phase 4)

Deficiency Diseases (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 2)

Drug Interactions (Phase 1)

Endothelial Cells (Phase 2/Phase 3)

Gout ()

Healthy Volunteers (Phase 1)

Heart Failure, Diastolic (Phase 4)

Hypertension (Phase 4)

Hyperuricemia ()

Joint Diseases (Phase 2)

Kidney Calculi (Phase 2)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2/Phase 3)

Metabolic Syndrome (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 2)

Prehypertension (Phase 4)

Pulse Wave Analysis (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Therapeutic Equivalency (Phase 1)

Tumor Lysis Syndrome (Phase 3)

Urination Disorders (Phase 2)

Urolithiasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 81
  • # of Trial Organizations: 79

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue